LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

2.06 -5.5

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.06

Max

2.18

Põhinäitajad
By Trading Economics
Sissetulek	14M -1M
Müük	16M 21M
Aktsiakasum	-0.003
Kasumimarginaal	-4.943
Töötajad	81
EBITDA	14M -996K

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+84.86% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	249M 959M
Eelmine avamishind	7.56
Eelmine sulgemishind	2.06

Uudiste sentiment

By Acuity

58%

42%

269 / 344 Pingereas Healthcare

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. juuni 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1. juuni 2026, 23:38 UTC

Omandamised, ülevõtmised, äriostud

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1. juuni 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1. juuni 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. juuni 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1. juuni 2026, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. juuni 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. juuni 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1. juuni 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Greg Abel's Week Is Off to Quite a Start -- WSJ

1. juuni 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1. juuni 2026, 21:22 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1. juuni 2026, 20:46 UTC

Omandamised, ülevõtmised, äriostud

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1. juuni 2026, 20:22 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Declares $11 Special Div

1. juuni 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1. juuni 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1. juuni 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1. juuni 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1. juuni 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1. juuni 2026, 18:54 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1. juuni 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1. juuni 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1. juuni 2026, 18:00 UTC

Omandamised, ülevõtmised, äriostud

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1. juuni 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1. juuni 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. juuni 2026, 17:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

84.86% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 84.86%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

269 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.